Rapid clinical deteriorations have been reported after abrupt discontinuation of clozapine. A 42-year-old psychiatric patient presented with ingestion of hand-disinfectant solutions causing transient impairment of his conscious level. His clozapine therapy was discontinued for a short period of time and he developed delirium with normal results of investigations for underlying organic causes. His delirium resolved rapidly after the reintroduction of clozapine. The withdrawal effects of abrupt discontinuation of clozapine are discussed in this article.
Introduction
Clozapine is an atypical antipsychotic drug for the treatment of previously resistant schizophrenic patients. 1 It has a special chemical profile with low blockade of D2 receptors and high affinity for D1 and D4 receptors and also muscarinic and 5-HT2 receptors. Its main advantage over conventional anti-psychotics is the low incidence of extrapyramidal side effects due to the low affinity for the D2 receptor. 2 Serious side effects of clozapine include agranulocytosis 3 and myocarditis/cardiomyopathy. 4 Abrupt discontinuation of clozapine may lead to supersensitivity psychosis, 5 cholinergic rebound 6 and catatonia. 7, 8 We report a case of a psychiatric patient presenting with delirium after abrupt discontinuation of clozapine. Reintroduction of clozapine resulted in rapid improvement of his mental state.
Case
A 42-year-old gentleman was brought to the accident and emergency department (AED) for impaired conscious level in December 2008. He had history of schizophrenia and was an in-patient in a psychiatric hospital. He had been put on clozapine since 1998 and was well-maintained at the dose of 50 mg at 5 pm/450 mg at 8 pm. There was no other concomitant psychiatric medication apart from clozapine. He was all along well until two hours before arrival and was found to be sleepy by the psychiatric hospital staffs. The dose of clozapine at 5 pm was withheld. He vomited out clear fluid with 'strong alcohol smell' around 10 minutes before arrival. He was then transferred for management of suspected ingestion of "alcohol-based" hand-disinfectant solution. At presentation, he had a Glasgow Coma Scale score (GCS) of 8/15 (E2V1M5), blood pressure 120/80 mmHg, pulse rate 107/min, SpO 2 94% on room air and body temperature 35.9°C. The physical examination revealed no external wound, clear chest with good respiratory effort and no focal neurological deficit. His muscle tone was normal. He was put on high flow oxygen via facial mask with SpO 2 maintained at 99%. The electrocardiogram showed sinus tachycardia with heart rate of 108 beats per minute, QRS complex of 120 ms and no ST segment change. Bedside glucose level and blood gas analysis were normal. The chest X-ray showed clear lung field and computed tomography of his brain showed no intracerebral haemorrhage. He was subsequently transferred to the Emergency Medicine Ward for further management and close observation.
Subsequent blood tests showed mild leukocytosis with white blood cells (WBC) of 11.3 x 10 9 /L, normal renal and liver function. The first creatine kinase (CK) level taken on arrival at the AED was mildly elevated (349 U/L). Paracetamol, salicylate and ethanol levels were all negative. In view of suspected toxic alcohol ingestion, e.g. isopropyl alcohol, osmolality gap was checked and found to be mildly elevated (12 mOsm/kg).
His conscious level gradually improved and he returned fully conscious around 8 hours after arrival. However, he developed confusion 4 hours later. Physical restraint was applied and two doses of haloperidol 5 mg were given intramuscularly 4 hours apart. Repeated blood tests revealed metabolic acidosis with pH 7.16, marked leukocytosis with WBC 17.2 x 10 9 /L and elevated CK level 6022 U/L around 5 hours after the first dose of haloperidol. An initial 5 mg of diazepam was given intravenously to control his confusional state but he became agitated again when the effect of diazepam weaned off. A regular oral dose of diazepam 5 mg was then prescribed every 8 hours. Subsequent blood tests showed the pH and osmolality gap normalised. His condition deteriorated with restlessness, agitation and refusal to eat. The physical examination revealed facial flushing, sweatiness and hypersalivation. There was 'stereotype-motion' over his thumbs with continuous rubbing over his fingers causing abrasions. He was all along afebrile with normal muscle tone. The CK level increased up to 23522 U/L on the third day of admission but the urine was all along clear. The WBC was static and the renal function was normal. He was treated with aggressive intravenous fluid therapy under close monitoring of central venous pressure and urine output. The psychiatrist was consulted. Diagnoses of delirium with underlying organic causes and suspected neuroleptic malignant syndrome (NMS) were made. Bromocriptine was started. Investigations for acute delirium, including thyroid function, septic workup, lumbar puncture and electroencephalography were normal. Serum iron was within normal range. The CK level gradually decreased to 19519 U/L and 13713 U/L on the fourth day of admission. However, there was no obvious improvement of his mental state with vigorous struggle and disorganised speech. Withdrawal symptoms secondary to the discontinuation of clozapine therapy were suspected. A low dose of clozapine (50 mg at 5 pm and 50 mg at 8 pm) was reintroduced. His condition began to improve the next morning and he became fully alert around 19 hours after restarting clozapine. The dose of clozapine was then gradually increased to 50 mg at 5 pm/250 mg at 8 pm, 3 days later and the patient was subsequently transferred back to the psychiatric hospital after 8 days of hospitalisation.
Discussion
Our patient had well control of his psychotic symptoms on long term clozapine all along and he even managed to take up some daily duties in the psychiatric hospital. The initial impaired conscious level was likely due to the ingestion of hand disinfectant solution which may contain isopropanol. Ingestion of isopropanol can cause central nervous system depression and increased osmolality gap with absence of metabolic acidosis. 9 Individual toxic alcohol levels were not analysed in our patient as there was only transient change of the osmolality gap. More detailed history was obtained after the patient became fully conscious and he admitted the ingestion of hand-disinfectant solution which was brought by the relatives of other patients on the day of admission. The subsequent transient episode of metabolic acidosis might be due to tissue hypoperfusion secondary to vigorous movement of the patient under physical restraint. The recurrence of confusion after consciousness improvement for 4 hours in our patient was likely due to causes other than the alcohol ingestion.
NMS was initially suspected due the progressive increase of CK level after haloperidol injections. However, physical restraint could contribute to the marked elevation of CK level and the diagnosis of NMS was in doubt based on the following discussion.
Did the patient develop NMS?
The diagnosis of NMS required the association with antipsychotic agent exposure and a tetrad of specific clinical features: fever, rigidity, mental status change and autonomic dysfunction. 10 According to the DSM-IV diagnostic criteria for NMS, diagnosis of NMS requires the development of severe muscle rigidity and elevated temperature associated with the use of neuroleptic medications plus two or more of a list of clinical features, i.e. diaphoresis, dysphagia, tremor, incontinence, change in level of consciousness, mutism, tachycardia, elevated or labile blood pressure, leukocytosis and laboratory evidence of muscle injury. In addition, the symptoms cannot be accounted for by other substances, neurological or general medical conditions and mental disorders. 11 As there were only altered mental state, leukocytosis and elevated CK level present in our patient, the diagnostic criteria for NMS could not be completely fulfilled. Moreover, the serum iron level was normal and a low serum iron concentration was found to be a sensitive marker for NMS. 12 Based on the clinical and laboratory evidence, the possibility of NMS was believed to be low but could not be absolutely ruled out as atypical features of clozapine-induced NMS had been reported.
Our patient was treated as NMS with bromocriptine, a dopamine agonist, because of the potential fatal complications from NMS. The CK level decreased with intravenous fluid therapy and bromocriptine. However, his impaired mental state persisted.
Was there a role of clozapine, an atypical antipsychotic, in inducing NMS in our case?
Two hypotheses were considered: (1) clozapineinduced NMS; (2) NMS induced by the combination of haloperidol and abrupt discontinuation of clozapine.
(1) Clozapine-induced NMS
NMS is a potentially fatal idiosyncratic complication of neuroleptic treatment and is a well recognised, serious side effect of conventional antipsychotic agents. The underlying pathophysiology is thought to be a sudden blockade of D2 dopamine receptors. The frequency of occurrence of the NMS with conventional antipsychotic drugs has been reported to be from 0.02% to 2.44%. 13 The incidence of atypical antipsychotic causing NMS is unknown. Ananth et al reviewed 68 cases of NMS associated with atypical antipsychotic drugs that met the DSM-IV criteria in which 21 cases involved clozapine. The mean onset time and the mean recovery time of NMS associated with clozapine were 218 days and 10.7 days respectively. Atypical antipsychotic drug-induced NMS manifested extrapyramidal symptoms less frequently (78%) and the mortality rate was lower (3 out of 68) compared with conventional antipsychotic agents.
14 The lower mortality rates associated with atypical antipsychotic drugs may only indicate a lower threshold of diagnosis and early detection due to close monitoring of clozapine-treated patients for agranulocytosis. NMS has been reported in a patient after more than 10 years of clozapine treatment. 15 Thus, we could not rule out the possibility of clozapineinduced NMS in our patient just basing on the long duration of clozapine therapy. Sachdev et al compared cases of clozapine-related NMS with cases of NMS associated with conventional neuroleptic drugs. Similar to findings as Ananth et al, patients with clozapine-related NMS manifested atypical features with fewer extrapyramidal symptoms, muscle rigidity and smaller rise of CK level. 16 
(2) NMS induced by the combination of haloperidol and abrupt discontinuation of clozapine
Mendhekar has reported a case of NMS precipitated by a single dose of parenteral haloperidol in a patient with abrupt discontinuation of clozapine. 17 It was postulated that cholinergic rebound occurred after abrupt discontinuation of clozapine and the dopamine-acetylcholine imbalance secondary to the abrupt discontinuation of clozapine might predispose the patient for NMS on exposure to potent dopamine antagonist.
NMS vs. Clozapine withdrawal
There was a therapeutic dilemma on the management of our patient. The two assumptions were: (1) Clozapine induced NMS; (2) Clozapine withdrawal. The incidence of deterioration of psychotic symptoms after abrupt clozapine withdrawal has been reported ranging from 7.5% to 88.9%. [18] [19] [20] The risks were higher in patients on high doses of clozapine therapy. 21 This 'rebound phenomenon' can manifest as rapid psychotic exacerbation (supersensitivity psychosis) and/or cholinergic rebound.
The pathophysiological basis of this phenomenon is thought to be supersensitivity of mesolimbic dopamine receptors, cholinergic rebound and serotonergic hyperactivity. [22] [23] [24] Patients who received anticholinergic drugs were less likely to develop symptoms of clozapine withdrawal. 25 Durst et al reported a case series of serious deterioration and psychotic exacerbation after abrupt cessation of clozapine with dosages ranging from 300 mg/day to 425 mg/day. The onset time of withdrawal symptoms ranged from within 48 hours to within one week. 22 Shiovitz et al evaluated the abrupt withdrawal effects in 28 patients taking clozapine 200 mg/day for about one month. Eleven of them had no withdrawal adverse events, 12 had mild withdrawal adverse events and 5 experienced moderate or severe withdrawal symptoms. For those patients with moderate or severe symptoms, the onset time ranged from 24 hours to 3 days. 23 Rapid improvement of delirium and psychotic symptoms could be achieved by resumption of a low dose of clozapine. 5, 26 Our patient developed delirium around 32 hours after the last dose of clozapine. Considering the timeframe for the onset of symptoms, the clinical presentations of our patient were compatible with the withdrawal effects arising from the abrupt discontinuation of the clozapine therapy. A low dose of clozapine was reintroduced and a rapid response was observed in our patient.
Conclusion
Abrupt clozapine discontinuation may result in delirium. Vigilance is the key for early recognition. Prompt reintroduction of clozapine leads to dramatic clinical recovery.
